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Congenital diseases are responsible for over a third of all pediatric hospital admissions.
Advances in prenatal screening and molecular diagnosis have allowed the detection of
many life-threatening genetic diseases early in gestation. In utero transplantation (IUT)
with stem cells could cure affected fetuses but so far in humans, successful IUT using
allogeneic hematopoietic stem cells (HSCs), has been limited to fetuses with severe
immunologic defects and more recently IUT with allogeneic mesenchymal stem cell
transplantation, has improved phenotype in osteogenesis imperfecta. The options of
preemptive treatment of congenital diseases in utero by stem cell or gene therapy
changes the perspective of congenital diseases since it may avoid the need for postnatal
treatment and reduce future costs. Amniotic fluid stem (AFS) cells have been isolated and
characterized in human, mice, rodents, rabbit, and sheep and are a potential source of
cells for therapeutic applications in disorders for treatment prenatally or postnatally. Gene
transfer to the cells with long-term transgenic protein expression is feasible. Recently, pre-
clinical autologous transplantation of transduced cells has been achieved in fetal sheep
using minimally invasive ultrasound guided injection techniques. Clinically relevant levels
of transgenic protein were expressed in the blood of transplanted lambs for at least
6 months. The cells have also demonstrated the potential of repair in a range of pre-
clinical disease models such as neurological disorders, tracheal repair, bladder injury, and
diaphragmatic hernia repair in neonates or adults. These results have been encouraging,
and bring personalized tissue engineering for prenatal treatment of genetic disorders closer
to the clinic.
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INTRODUCTION
Congenital diseases attributed to about 510,000 deaths globally
in 2010 (Lozano et al., 2012), and are estimated to contribute
to over a third of pediatric admissions to the hospital and up to
50% of the total costs of pediatric hospital treatment (McCandless
et al., 2004). Prenatal diagnosis of many congenital diseases are
performed using traditional invasive techniques such as amnio-
centesis or chorionic villus sampling (CVS), but increasingly non-
invasive methods using circulating fetal DNA in the maternal
blood are feasible and available for prenatal diagnosis early in
gestation (Danzer et al., 2012; Danzer and Johnson, 2014). The
current options for most parents facing congenital diseases fol-
lowing prenatal diagnosis are either to terminate or continue with
a known affected pregnancy.
Progress over the last two decades have resulted in fetal
therapy being available for a small number of congenital struc-
tural anomalies such as spina bifida, identical twin placental
complications, and congenital diaphragmatic hernia, using open
surgical or fetoscopic interventions (Pearson and Flake, 2013).
These options are currently restricted to the treatment of fetal
pathophysiology and are usually performed in the second half of
gestation, when pathology is already evident. There are almost no
therapeutic options however for life-threatening genetic disorders
which have pathology beginning in utero. Success with in utero
transplantation (IUT) using allogeneic hematopoietic stem cells
(HSCs), has been limited to fetuses with severe immunologic
defects where there is an effective lack of immune response to
allogeneic cells, and transplanted genetically normal cells have
a proliferative advantage (Tiblad and Westgren, 2008). Mes-
enchymal stem cells (MSCs) appear to be less immunogenic
than their hematopoietic counterparts (O’Donoghue and Fisk,
2004) and have shown to reduce fracture rate in a mouse model
(Guillot et al., 2008) and engraft in human fetuses with osteoge-
nesis imperfecta in an allogeneic setting (Horwitz et al., 2002).
Attempts to treat diseases such as sickle cell disease (Westgren
et al., 1996) with in utero HSC transplantation, have been
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unsuccessful, even where a suitably matched donor has been avail-
able. Mouse studies suggest that the immune barrier to allogeneic
in utero HSC transplantation may be stronger than previously
thought (Peranteau et al., 2007). Transplantation of autologous
progenitor cells, which have been corrected for the disease, could
avoid the fetal immune barrier and may prove more successful
than allogenic progenitors.
Autologous progenitors can be obtained from the fetus itself.
Both proliferative and differentiation potentials of amniotic fluid
stem (AFS) cells has been demonstrated in vitro and in vivo (De
Coppi et al., 2007; Ditadi et al., 2009). Studies exploring the
potential of this stem cell source for the use in autologous or
allogenic prenatal therapy of congenital diseases have been con-
ducted in large animal models (Shaw et al., 2014). In this review,
we explore the latest developments in the field of in utero therapy
for congenital disorders such as stem cell transplantation and gene
transfer using AFS and their potential clinical applications.
AMNIOTIC FLUID AS A FETAL CELL SOURCE FOR IN UTERO
THERAPY
Amniotic fluid (AF) consists of cells of fetal origin such as the
amnion, skin, and respiratory system (Prusa and Hengstschläger,
2002; Tsai et al., 2004) and it can be obtained by routine clinical
amniocentesis during pregnancy, a minimally invasive procedure
used for prenatal diagnosis that usually takes place from 15 weeks
of gestation (Gosden, 1983; Prusa and Hengstschläger, 2002;
Delo et al., 2006). AF can also be collected during therapeutic
amniodrainage procedures or even at cesarean section surgeries.
Other fetal stem cell sources include the placenta, which can be
accessed via ultrasound-guided CVS from 11 weeks of gestation
or after birth yields epithelial, hematopoietic, and MSC types
(Pipino et al., 2013; Jones et al., 2014). Fetal blood and the HSCs
therein can also be collected from the umbilical cord in the first
trimester of pregnancy by thin-gauge embryo fetoscopic-directed
or ultrasound-guided blood sampling, although the long-term
outcome following this procedure is not known (Chan et al.,
2008).
In recent years, AFS cells have been explored in many clini-
cal applications such as tissue engineering, cell transplantation,
and gene therapy (Kaviani et al., 2001, 2003; Fauza, 2004; Tsai
et al., 2004). C-Kit+ cells can be successfully isolated from AF,
expanded with good population doublings and possess a very well
characterized phenotype (Tsai et al., 2004; Delo et al., 2006; De
Coppi et al., 2007; Ghionzoli et al., 2010). The surface antigen
c-Kit (CD117) is known to be the receptor of stem cell factor
and plays an essential role in gametogenesis, melanogenesis, and
hematopoiesis (Fleischman, 1993; De Coppi et al., 2007). The
successful expansion of AFS c-Kit+ cells has led to the find-
ing of unique cell types such as mesenchymal (AFMSCs) and
hematopoietic progenitors (Prusa and Hengstschläger, 2002; Delo
et al., 2006; De Coppi et al., 2007; Ditadi et al., 2009).
Human AFS cells give rise to a variety of cell types such as
osteogenic, myogenic, adipogenic, endothelial, hepatic, and neu-
ronal origin; differentiation which has been be validated by the
expression of mRNAs in lineage specific genes (Tsai et al., 2004; De
Coppi et al., 2007). Rodent and murine AFS cells, like human AFS
cells share similar growth properties and differentiation potential
in vitro as well as the expression of embryonic and adult stem cell
markers, respectively (De Coppi et al., 2007). AFS cells derived
from human, mice, and sheep can be easily transduced without
losing their characteristics (De Coppi et al., 2007; Ditadi et al.,
2009; Mehta et al., 2011; Shaw and Bollini, 2011), and they possess
privileged immunological characteristics that make them an ideal
and reliable source for therapeutic transplantation (Ditadi et al.,
2009).
The immune modulatory properties of AFS have shown resis-
tance to natural killer (NK) cytotoxicity by inflammatory priming
of AFS with interferon gamma (IFN-γ) and tumor necrosis factor
alpha (TNF-α) and its ability to modulate lymphocyte prolifer-
ation according to its gestational age (Di Trapani et al., 2014).
For instance, IFN-γ increases both MHC Class I and MHC Class
II expression, indicating that like MSCs, they may not strongly
contribute to rejection responses in allogeneic hosts (Moorefield
et al., 2011). Moreover, AFS have shown to release high levels
of cytokines including IL-6, MCP-2, MIP-3α, and MIP-1α when
activated suggesting that they possess alternative molecular mech-
anisms to modulate immune response and regulation (Perin et al.,
2010; Moorefield et al., 2011).
GROWTH AND CHARACTERIZATION OF AMNIOTIC FLUID-DERIVED
STEM CELLS
AFS cells have an estimated doubling time of 36 h and are
grown without feeder layers (De Coppi et al., 2007). MSC sub-
populations of AFS cells (AFMSCs), like other MSCs, maintain
their spindle-shaped fibroblast-like morphology, their prolifera-
tion rate as well as their differentiation potential. Growth kinetics
assays have shown that AFMSCs have a higher proliferation rate
with an average doubling time of 25–38 h compared to bone
marrow (BM) derived-MSCs that have an average doubling time
of 30–90 h (Kaviani et al., 2001; Roubelakis et al., 2007). In
addition, AFMSCs have a greater clonogenic potential compared
to BM-MSCs (86 ± 4.3 versus 70 ± 5.1 colonies; Nadri and
Soleimani, 2007). Despite the high proliferative rate of AFMSCs,
they are still able to retain a normal karyotype with no evidence of
tumorigenicity (Roubelakis et al., 2007). Human AFS cells express
both markers of mesenchymal and pluripotent stem cells origin,
such as stage-specific embryonic antigen (SSEA)-4 and Oct-4 (De
Coppi et al., 2007). Once cultured in adherence however, they
do not express markers of hematopoietic lineage such as CD45,
CD34, and CD133 and express CD29, CD44, CD73, CD90, and
CD105 (De Coppi, 2013). Interestingly, their plasticity, which
is superior to adult stem cells, allow reprogramming into AFS
derived induced pluripotent stem cells (iPS) with the change
of the culture conditions they are exposed to (Lu et al., 2012;
Moschidou et al., 2012, 2013; Pipino et al., 2014). This is par-
ticularly relevant as AFS cells can be utilized for cell banking of
patient-specific pluripotent cells for potential applications in allo-
geneic cellular replacement therapies, pharmaceutical screening,
and disease modeling (Moschidou et al., 2012, 2013).
In addition AFS cells, similarly to other fetal cells may rep-
resent the ideal source for therapy because, similarly to ES
cells, they are easy to expand, and, in common with the adult
counterparts, they are less controversial, not tumorigenic, readily
cryopreserved for cell banking and their use can be accomplished
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on an autologous setting (De Coppi, 2013). The latter is particu-
larly important in neonatal surgery, in the context of congenital
malformations.
GENE TRANSFER TO AMNIOTIC FLUID STEM CELLS
To be a successful autologous therapeutic resource for correcting
genetic disease, AFS cells must be easily transduced to give high
levels of therapeutic transgenic protein expression. The trans-
duction of human AFS cells with vectors was explored with
recombinant adenovirus vectors containing reporter genes such
as AdHCMVsp1LacZ and AdCMV.eGFP (Grisafi et al., 2008).
Human AFS cells presented a transduction efficiency of 100%
when infected with 50 pfu/cell. Transduced human AFS cells
maintained stemness features such as the expression of stem cell
markers (SSEA4 and OCT4), adhesion and stromal molecules
(CD29 and CD73) as well as adipogenic and osteogenic differ-
entiation potential after infection (Grisafi et al., 2008). However,
a decrease in SSEA4 expression, no expression of lipoprotein
lipase (Lpl), an important adipogenic gene during differentiation
and the expression of transcription factors Cbfa1 and PPaRγ
detected only during early stages of differentiation suggests a
slowdown in the differentiative progression and pluripotency
after transduction.
Recently, we have shown that sheep AFS cells have the ability
to be transduced using a lentivirus vector encoding the HIV-1
central polypurine tract element, the spleen focus forming virus
LTR promoter, and the marker gene eGFP (63.2% efficiency).
They have the ability to maintain the expression of MSC markers
(CD44, CD58, and CD166) but were negative for hematopoietic,
and endothelial markers (CD14, CD31, and CD45) as well as
differentiate into adipogenic and osteogenic lineages (Shaw and
Bollini, 2011; Shaw et al., 2014).
IN UTERO TRANSPLANTATION
IUT involves the transplantation of cells to the fetus in utero
(Muench, 2005) with the aim of treating congenital disorders by
providing the correct stem cells (IUSCT) or gene corrected stem
cells (IUSCGT). The benefits of an in utero approach to correcting
genetic disease includes the prevention of pathology when it arises
antenatally in those genetic diseases that cause irreversible damage
to organs in utero, targeting of stem cell progenitors that are
abundant and accessible in the fetus as well as dose scaling where
the small size of the fetus allows relatively high doses of cells to be
delivered. There is an opportunity for engraftment of donor cells
without the need for myeloablation due to the immature status
of the fetal immune system prior to thymic processing of self-
antigen, a normal event in hematopoietic ontogeny (Waddington
et al., 2007; David and Peebles, 2008; Shaw et al., 2011). Further-
more, immunological tolerance would allow postnatal reinfusion
of cells to boost the effect after birth, as demonstrated recently in
two children with osteogenesis imperfecta treated by IUT using
MSCs (Götherström et al., 2014). Postnatal reinfusion with more
MSCs from the original infusion source resulted in improved
growth rate after birth.
As with any new therapeutic modality, the risks of IUT are
not well characterized and the efficacy is still to be determined
for some diseases. For in utero gene therapy, where vectors are
given directly to the fetus for correction of genetic disease there
has been direct guidance given by the NIH Recombinant DNA
advisory committee report (RAC, 2000) on a pre-proposal for the
initial application. The recommendations included that treatment
should be limited only to: diseases that carry serious morbidity
and mortality risks for the fetus either in utero or postnatally, do
not have an effective postnatal therapy, or have a poor outcome
using available postnatal therapies, can be definitively diagnosed
in utero and have a well-defined genotype/phenotype relationship,
have an animal model for in utero gene transfer that recapitulates
the human disease and that the therapy would correct all serious
abnormalities. It was recognized that a direct fetal vector injection
approach would be difficult to justify given the above.
A combination IUSCGT approach however seems more likely
to be acceptable. The UK Gene Therapy Advisory Committee
(GTAC) considered this in their broader judgments about gene
therapy in utero (Eckstein, 2003). The New and Emerging Tech-
nologies subgroup of GTAC found that the use of genetically
modified stem cells in stem cell transplantation to the fetus
was a possibility stating “such ex vivo modification would be
unlikely to carry with it any higher risk to the germ line than the
trials of postnatal somatic gene therapy which have already been
approved.”
DEVELOPMENT OF THE FETAL IMMUNE SYSTEM AND BARRIERS TO
ENGRAFTMENT AFTER IUT
The fetal immune system is commonly regarded as immature
and unresponsive despite reports showing its functional immune
response (Mold and McCune, 2012). IUT relies crucially on the
concept that the developing fetal immune system might accept a
foreign cell or antigen and become tolerant to it. The presence of
human NK cells have been detected as early as gestational week
6 in the fetal liver and in the fetal spleen at gestational week 15
(Phillips et al., 1992). Fetal NK cells have the ability to differentiate
early in utero and are highly responsive to cytokines and antibody-
mediated stimulation, and have shown to be functionally imma-
ture compared to adult NK cells (Phillips et al., 1992; Ivarsson
et al., 2013).
The immune system during early gestation undergoes a pro-
cess of self-education that occurs in the thymus. The positive
and negative selection of pre-lymphocytes for the recognition of
“self ” major histocompatibility complex (MHC) antigen allows
a repertoire of lymphocytes to be capable of direct and indirect
antigen presentation which results in the deletion of alloreactive
T-cells, regulatory T cells (Tregs) enrichment and creates donor-
specific immune tolerance (Nijagal et al., 2013). Thus, to prevent
limited engraftment, transplants should be introduced prior to
the appearance of mature T-cells in the fetal thymus (Peranteau
et al., 2006; Roybal et al., 2010; Nijagal et al., 2013).
In the human fetus, the immune system develops from 12 to
14 weeks of gestation, when profound increases in circulating T
lymphocytes can be observed (Darrasse-Jèze et al., 2005; Taka-
hama, 2006). Delivery of gene therapy may be required before this
gestational age, which currently could limit the routes of appli-
cation that can be safely used, although advances in engineering
and imaging is leading to large improvements in fetal imaging
and injection systems. It was demonstrated that the human fetus
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may have developed a functional immune system during the
second trimester of gestation (Tse et al., 2005). Hematological
compositions of human fetal blood and liver between 8 and
17 weeks gestation showed an increase in fetal red blood cell, white
blood cell, and platelet counts with advancing gestation reflect-
ing hematologic development (Pahal et al., 2000). An increase
in circulating and hepatic T lymphocytes showed the presence
of thymic maturation before the 13th week of gestation while
the proportion of circulating primitive hematopoietic stem and
progenitor cells decreased after each successive gestational week.
These findings support the concept of introducing IUT before the
13th week of gestation to induce actively acquired specific toler-
ance to the foreign antigen (Pahal et al., 2000). Thus, IUT could be
performed to the corresponding hematopoietic compartments or
systemically depending on the gestational age the transplantation
occurs (Tavian and Peault, 2005).
Studies in mice strongly support there being an immune
barrier to allogeneic engraftment after IUHCT. Transplantation
of allogenic HSCs at day 14 post conception gave initially similar
results to IUT with congenic HSCs at 1 week of age (100%)
but after 6 months, engraftment dropped rapidly (19% allogenic
versus 100% congenic; Muench, 2005; Tse et al., 2005; Peran-
teau et al., 2007; Shaw and Bollini, 2011). Strategies to improve
engraftment of allogenic HSC in utero have include the use of
busulfan, cotransplantation of LLME-treated, MHC-sensitized
donor lymphocytes, CD26 inhibition and using haploidentical
HSC sources (Hayashi et al., 2004; Ashizuka et al., 2006; Vrecenak
et al., 2014). For instance, low-levels of allogeneic chimerism
could be enhanced to near-complete donor chimerism in murine
models by postnatal minimally myeloablative total body irradia-
tion (TBI) followed by same-donor BM transplantation (Peran-
teau et al., 2002). Due to the concerns with toxicity, minimally
toxic postnatal regimens such as busulfan conditioning have been
studied and shown to improve therapeutic levels of allogeneic
engraftment (Ashizuka et al., 2006). Mice with <1 and >1%
chimerism, had 60 and 100% enhanced engraftment, respectively
(Ashizuka et al., 2006).
Maternal T cells play a key role in the success in utero therapy
by being a barrier to engraftment (Nijagal et al., 2011). There
were no differences observed in engraftment of syngeneic and
allogeneic fetal recipients when cells were matched to the mother
in a murine model. It is believed that the immune barrier may
result from maternal pathogenic immune responses as a result
of pro-inflammatory signals released during fetal intervention
(Nijagal et al., 2011). Recent studies of canine IUT with HSCs
in utero were encouraging. A time of 40 days gestation (term
63 days) was chosen for these experiments since it was at the
initiation of thymic selection, and prior to BM hematopoiesis,
therefore being optimal for engraftment. Intracardiac injection
was the most efficient delivery method giving much higher levels
of donor cell engraftment than intraperitoneal injection. The
authors achieved stable long-term multilineage engraftment in
21 of 24 surviving recipients with an average level of initial
chimerism of 11.7% (range 3–39%) without conditioning and
with no evidence of graft versus host disease (GVHD). Donor cell
chimerism remained stable for up to 2 years and was associated
with donor specific tolerance for renal transplantation (Vrecenak
et al., 2014). Intracardiac injection early in gestation currently
carries an increased risk of miscarriage in clinical practice com-
pared to intraperitoneal injection, but these findings suggest that
clinically relevant levels of engraftment might be achievable using
this approach and research is underway to evaluate safety and
feasibility in relevant pre-clinical animal models prior to the first
human studies. Using stem cells that are matched to the fetus,
i.e., autologous cells, is an alternative approach which is discussed
further on in this review.
SEVERE COMBINED IMMUNODEFICIENCY
Severe combined immunodeficiency (SCID) has been successfully
corrected by ultrasound guided intraperitoneal or intravenous
fetal injection of HSCs derived from the paternal BM or an
allogeneic fetal liver (Flake et al., 1996; Westgren et al., 2002). X-
linked SCID is an immunodeficiency caused by the mutation of
IL2RG, which encodes the cytokine-receptor γ chain that results
in a block in T-cell development and a severe deficiency of mature
T cells (Flake et al., 1996). After IUSCT, stable split chimerism
with the T-cell lineage of donor origin and all other lineages of
host origin was seen postnatally in treated individuals as evidence
of immune system reconstitution (Flake, 2004). For most patients,
the diagnosis of SCID is only made in the neonatal period mean-
ing that postnatal treatment is the only option. Rapid advances
in fetal medicine, such as the availability of non-invasive prenatal
diagnosis in the first trimester is likely to make prenatal screening
a reality. IUSCT currently is an option for affected families that
have a one in four risk of recurrence, where first trimester prenatal
diagnosis can be made by CVS leaving time to perform stem cell
transplantation using allogeneic stem cells. The most common
treatment for SCID patients is a postnatal BM transplant where
a matched donor is required. More recently, where a suitable
donor is not available, a stem cell gene therapy approach has used
gene corrected autologous BM transplantation with great success
(Demaison et al., 2002; Gaspar and Thrasher, 2005; Thrasher
et al., 2006; Gaspar et al., 2011; Montiel-Equihua et al., 2012). For
instance, in 2012, around 30 patients had been treated most of
whom had experienced clinical benefit with the absence of any
vector-related complications (Gaspar and Thrasher, 2005). There
is a chance of insertional mutagenesis occurring during retroviral
and lentiviral vector integration into host-cell chromosomes as
well as the development of lymphoproliferative disease in individ-
uals with SCID (Gaspar and Thrasher, 2005; Yáñez-Muñoz et al.,
2006; Howe et al., 2008). It is important for clinical therapies to
achieve stable transgene expression while minimizing insertional
mutagenesis (Baum et al., 2003). Integration-deficient lentiviral
vectors and self-inactivating (SIN) gammaretroviral vectors have
a low risk and in cellular and in vivo models of SCID can mediate
stable transduction (Yáñez-Muñoz et al., 2006; Thornhill et al.,
2008).
CONGENITAL BLOOD DISORDERS
Inherited blood disorders such as the hemoglobinopathies or
clotting disorders would be a relatively simple target for IUT as the
fetal circulation can be reached through the umbilical vein (UV)
at the placental cord insertion or the intrahepatic UV, or even via
the peritoneal cavity, a route used successfully to transfuse anemic
fetuses.
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Prenatal screening and diagnostic services for congenital
hemoglobinopathies are available in many countries making them
an attractive option for an in utero therapeutic approach (David
and Waddington, 2012). Prenatal diagnosis can be achieved cur-
rently from 11 weeks of gestation using CVS, or amniocentesis
from 15 weeks, but increasingly there are advances in non-
invasive prenatal screening and diagnosis using circulating fetal
DNA detected in the maternal plasma allows the diagnosis of
congenital disorders as early as 7 weeks (Lo et al., 1998). Since AF
or chorionic villus samples are accessible relatively easily and early
in pregnancy, they would provide the potential for therapeutic use
after clinical prenatal diagnosis have been performed.
Inherited abnormalities of hemoglobin (Hb), a tetramer of
two α-like and two β-like globin chains, are a common and
global problem. Over 330,000 affected infants are born annu-
ally worldwide, 83% with sickle cell disorders and 17% with
thalassemias (Modell and Darlison, 2008). Current treatment
of β-thalassemia is by postnatal allogeneic hematopoietic stem
cell transplantation (HSCT) which can cure the condition with
recent results of 90% survival and 80% thalassemia-free survival
(Angelucci et al., 2000). However, this option is only available in
approximately 30% of cases due to the lack of a suitable matched
donor (Lucarelli, 2002), and it is associated with complications
such as GVHD. For children where HSCT is unavailable, they
are dependent on blood transfusions that result in iron overload,
and the need for iron chelation therapy. In alpha-thalassemia,
some individuals who make very little or no α globin chains, have
severe anemia, termed Hb Bart’s hydrops fetalis syndrome which
is commonly diagnosed prenatally and if untreated causes death
in the neonatal period (Harteveld and Higgs, 2010). Current
treatment of sickle cell relies on a number of strategies such as
the use of prophylactic antibiotics, pneumococcal vaccination and
good hydration, and effective crisis management such as using
oxygen and pain-relief (Meremikwu and Okomo, 2011).
Attempts to cure thalassemia and sickle cell disease using
gene therapy have been hampered by the large globin gene
and globin promoters that are difficult to accommodate within
vector systems. Amelioration or even cure of mouse models of
human sickle cell disease (Pawliuk et al., 2001) and β-thalassemia
major (Pawliuk et al., 2001; Persons et al., 2003; Puthenveetil
et al., 2004) has been achieved using lentivirus vectors that con-
tain complex regulatory sequences from the LCR region. Recent
advances in vector design have improved gene transfer for the
hemoglobinopathies such as the ubiquitous chromatin opening
element (UCOE) augmented spleen focus forming virus (SFFV)
promoter/enhancer which provides lentivirus vectors with a nat-
ural tropism for the hematopoietic system (Antoniou et al., 2003;
Williams et al., 2005) resulting in reproducible and stable function
in BM and all differentiated peripheral hematopoietic cell lineages
(Zhang et al., 2007).
Clotting disorders are caused by deficiencies in coagulation
factors, for example, hemophilia B, which is due to mutations
in the factor IX (F9) gene resulting in a deficiency in the blood
clotting protein human factor IX (hFIX; Waddington et al.,
2004b). The current treatment offered to patients with inherited
coagulopathies includes lifelong recombinant protein infusions,
which is required to avoid major pathology, and it is an expensive
and limited resource. In some patients, protein infusions can also
lead to the formation of antibodies to the infused product, which
prevents its use. Gene therapy cure of inherited coagulopathies
has come closer to reality with the use of adeno-associated virus
vectors (AAV). Animal experiments have shown AAV to be a
promising vector system and this has led to the first human
trials for this disease by applying AAV-hFIX intramuscularly to
eight adult patients with severe hemophilia B which showed a
small increase in hFIX plasma levels and a reduction in exoge-
nous protein requirement (Kay et al., 2000; Manno et al., 2003).
More recently, one trial used a self-complimentary AAV-hFIX
vector that gives higher levels of transgenic protein expression
in vivo than earlier single-stranded vectors. A single peripheral
vein infusion of a serotype-8-pseudotyped, self-complementary
AAV vector expressing a codon-optimized hFIX transgene in six
patients with severe hemophilia B (FIX activity, <1% of normal
values) gave FIX expression at 2–11% of normal levels in all
participants. A short course of glucocorticoid therapy normalized
raised liver enzyme levels that were observed in two patients
(Nathwani et al., 2011). AAV vectors with hFVIII and hFVII are
becoming available and are being tested in pre-clinical studies
(Binny et al., 2012; McIntosh et al., 2013).
Proof of principle studies have shown long-term expression
of hFIX proteins at therapeutic levels and induction of immune
tolerance (Waddington et al., 2007) after in utero gene therapy
using lentiviral vectors in mice (Waddington et al., 2004a,b).
More recently, using the same self-complementary AAV8 vector
expressing the human factor IX (hFIX) gene used for the clinical
trials, long-term hFIX expression was observed after ultrasound
guided intraperitoneal injection of fetal sheep in early and late
gestation (Nathwani et al., 2006; David et al., 2011). No functional
antibodies could be detected against the vector or transgene
product and no liver toxicity was observed. Antibodies to the
therapeutic gene were detectable when the animals were chal-
lenged at 6 months of age postnatally with the hFIX recombinant
protein, showing that induction of immune tolerance was not
achieved. This was probably due to the fall in hFIX expression
that was undetectable by 1 year after birth. UV delivery in fetal
non-human primates of a 10-fold higher dose of the same self-
complementary AAV system in late gestation produced clinically
relevant levels of hFIX sustained for over a year, with liver-specific
expression and a non-neutralizing immune response (Mattar
et al., 2011).
In utero transplantation for congenital blood disorders
In comparison to the relative success of postnatal transplantation
for blood disorders, results of clinical cases of IUT to cure blood
disorders have been disappointing (Nijagal et al., 2012; Pearson
and Flake, 2013). For instance, the transplantation of CD34+ cells
from either fetal liver or adult BM in cases of hemoglobinopathies,
showed no evidence of engraftment in all 22 cases with a clinical
outcome of lifelong blood transfusion or disease-related mortality
(Tiblad and Westgren, 2008). Attempts to treat other diseases such
as sickle cell or metabolic storage disorders have been unsuccessful
after fetal liver-derived stem cell transplantation, even wherein
a suitably matched donor has been available (D’Azzo, 2003;
Westgren, 2006).
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Transplantation of autologous derived fetal liver stem cells has
been attempted in the fetal sheep. Fetal liver stem cells collected
from first trimester preimmune sheep fetuses using ultrasound-
guided hepatic sampling were labeled with PKH26 and then
transplanted intraperitoneally into allogeneic and autologous
fetal recipients. Engraftment of donor cells was equivalent after
autologous or allogeneic transplantation (up to 4.7% in fetal liver,
spleen, BM, blood, and thymus) but the fetal loss rate was high
(29% allogeneic and 73% autologous transplantation) making
this technique difficult to justify in clinical practice (Schoeberlein
et al., 2004).
For coagulopathies, transplantation of MSCs may be a feasible
therapeutic option. In a sheep model of hemophilia A that reca-
pitulates the human condition (spontaneous bleeds and debilitat-
ing hemarthroses), encouraging results were found after postnatal
intraperitoneal infusion of paternally derived MSCs transduced
with a porcine FVIII-encoding lentiviral vector. Infusions of fac-
tor VIII were no longer required and damaged joints were fully
recovered. However, a sharp increase in pre-existent antibodies
occurred with time following transplantation which decreased the
effectiveness and limited the duration of therapy (Porada et al.,
2011). This emphasizes the need for an IUSCT approach for this
condition.
In utero stem cell gene therapy for congenital blood disorders using
AF-derived stem cells
Given the concerns around in utero application of gene therapy
directly to the fetus, our group have been studying whether a
combination of autologous transplantation with gene corrected
AFS might be a potential therapeutic approach. We have studied
the functional hematopoietic potential of transduced green fluo-
rescent protein (GFP)+ sheep AF-derived stem cells, before and
after autologous IUSCT. First trimester sheep AF was collected
by ultrasound-guided amniocentesis or at post mortem exami-
nation. We used a novel sheep CD34+ antibody that allows flow
cytometric detection of sheep HSC/progenitors present within
BM, cord blood, and mobilized peripheral blood. This antibody
also enriches for HSC/progenitors with enhanced in vitro colony-
forming potential (Porada et al., 2008). Sheep CD34+AF or adult
BM cells were selected and transduced overnight with an HIV
lentivirus vector containing eGFP. Transduced fresh or frozen
CD34+AF, or BM cells, were injected intravenously into NOD-
SCID-gamma (NSG) mice. GFP+ cells were detected in the
hematopoietic organs and peripheral blood of NSG mice primary
and secondary recipients 3 months later (Figure 1). Autologous
IUSCT was performed in fetal sheep using ultrasound-guided
intraperitoneal injection of fresh transduced GFP+CD34+AF
cells. GFP+ cells were detected in the peripheral blood of injected
lambs up to 6 months postnatally (Figure 2) and 3 months
after secondary transplantation of BM from autologous IUSCT
lambs into NSG mice, GFP+ cells were detected in hematopoietic
organs. This demonstration of autologous IUSCT of CD34+AF
cells in a large animal model supports the concept for clinical
translation to treat congenital hematopoietic diseases in utero
(Shaw et al., 2014).
Human β-thalassemia iPS have now been generated from
AFS using a single excisable lentiviral stem cell cassette vector.
AFS from the prenatal diagnosis of a β-thalassemia patient were
reprogrammed by expression of the four human reprogramming
factors Oct4, KLF4, SOX2, and c-MYC using a doxycycline lentivi-
ral system and demonstrated teratoma formation (Fan et al.,
2012). There are concerns that these iPS cells may be more likely
to develop teratomas than AFS cells that have a low risk of
this complication. This type of cell manipulation however, may
provide clinicians with corrected autologous patient-specific iPS
cells to use in a combination IUSCGT approach for the treatment
of thalassemia (Fan et al., 2012).
IN UTERO TRANSPLANTATION FOR OTHER CONGENITAL DISORDERS
IUT is a possible treatment strategy for congenital disorders
that affect organ systems other than the blood. These include
myelomeningocele (MMC; Danzer et al., 2012) which represents
the most severe form of spina bifida, cystic fibrosis (CF), lyso-
somal storage diseases such as acute neuronopathic (type II)
Gaucher disease, neuronal ceroid lipofuscinoses, and Niemann–
Pick disease type C, ornithine transcarbamylase deficiency (OTC),
as well as muscular dystrophy (David et al., 2003). Many of
these diseases and organ systems would be amenable to IUT
using MSCs, which compared to HSCs, are less immunologically
competent and may result in less transplantation related rejection
(O’Donoghue and Fisk, 2004).
In utero transplantation of mesenchymal stem cells
Human BM-MSCs have shown to have long-term engraftment
and have the ability to differentiate into various tissues when
transplanted into fetal sheep (Mackenzie and Flake, 2001). The
therapeutic potential for combining surgical repair and transplan-
tation of MSCs in utero has been demonstrated recently for the
treatment of spina bifida in a rat model (Li et al., 2012). IUT of
first trimester human fetal blood MSC ameliorates the skeletal
disorder in a mouse model of osteogenesis imperfecta (Guillot
et al., 2008). IUT of fetal MSCs reduced fracture rates and skeletal
abnormalities (Guillot et al., 2008). Two cases of IUT using
allogenic fetal liver MSC in the third trimester had encouraging
results with a successful engraftment which demonstrated 7.4%
chimerism at 9 months of age in one case and good long-term
outcomes (Le Blanc et al., 2005; Götherström et al., 2014).
In utero stem cell gene therapy using amniotic fluid-derived MSCs
High fetal survival was found after intraperitoneal injection of
autologous AFMSCs in the sheep (Mehta et al., 2011; Shaw
and Bollini, 2011). AF was collected under ultrasound-guided
amniocentesis in early gestation pregnant sheep (n = 9, 58 days of
gestation, term = 145 days) and AFMSCs were isolated, expanded,
and transduced using an HIV vector encoding enhanced GFP with
63.2% (range 38.3–96.2%) transduction efficiency rate (Figure 1).
Transduced AFMSCs were injected into the peritoneal cavity of
each donor fetal sheep at 76 days under ultrasound guidance with
a 78% overall survival rate for the full procedure. After 2 weeks,
GFP+ cells and protein was detected in fetal tissues including liver,
heart, placenta, membrane, umbilical cord, adrenal gland, and
muscle and this was further confirmed by cytofluorimetric and
immunofluorescence analysis (Figure 3).
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FIGURE 1 | Experimental design and injection procedure. After
amniocentesis collection, amniotic fluid mesenchymal stem cells (AFMSCs)
were cultured in adherence in defined conditions. Cells were transfected with
lentivirus GFP and re-injected into the peritoneal cavity of the fetal donor (A).
Transduced sheep eGFP+ CD34+ selected from fresh or frozen AF and adult
BM cells were transplanted into immunocompromised NSG mice (primary
and secondary xenogeneic transplantation) (B). Transduced sheep
eGFP+CD34+ fresh AF were also injected into donor sheep fetuses (in utero
autologous transplantation) that were subsequently delivered and followed for
up to 3 months of age. Bone marrow from these primary sheep recipients
was then used to perform xenogeneic secondary transplantation into NSG
mice (C). AF, amniotic fluid; BM, bone marrow. Sonograms showing
ultrasound guided amniocentesis (D) and intraperitoneal injection (E).
Amniocentesis was performed using a 22 gauge needle to collect 10 ml
amniotic fluid from the amniotic cavity around a fetal sheep at 58 days of
gestation. For intraperitoneal injection of transduced expanded amniotic fluid
cells we used a 20 gauge needle inserted through the anterior abdominal wall
of a sheep fetus at 76 days of gestation. Echogenicity can be seen throughout
the peritoneal cavity after injection of cells. Scale bars: 5 cm. (F) Timeline of
the experiment.
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FIGURE 2 | In utero autologous intraperitoneal transplantation of
sheep amniotic fluid CD34+ cells in fetal sheep with long-term follow
up. Engraftment in the peripheral blood after in utero transplantation of
autologous sheep CD34+eGFP+ AF cells. All five born lambs showed
eGFP+ cells in the peripheral blood at birth (M1-A, M2-A, M3-A, M2-B, and
M3-B), and all three survivors revealed persistent levels of engraftment of
around 2% that persisted up to the last sampling point at 6 months of age
(M1-A, M2-B, and M3-A). Negative control: peripheral blood from uninjected
sheep. M1, M2, and M3: the three ewes that showed negativity for eGFP
signal.
AFS cells intraperitoneally injected in a necrotizing enterocol-
itis rat model had shown improved survival, clinical status, gut
structure, and function (Eaton et al., 2013; Zani et al., 2014).
These findings suggest that the use of AFS cells as a source of cells
for in utero therapy could be an alternative way of ameliorating
prenatal congenital disease.
ROUTE TO THE CLINIC
Preclinical testing in animal models of disease will be an impor-
tant step before clinical translation is realized. There is no ideal
animal model and a balance is needed, taking into consideration
the gestational development of the organ to be targeted and
how that relates to its development in the human, the type of
placentation, fetal size, number and lifespan, parturition, and the
fetal and maternal immune response (Mehta et al., 2012; Mehta
and Abi-Nader, 2012). An assessment of the safety, accessibility,
transduction efficiency, and behavior of various stem cells (i.e.,
cord blood, placenta, AF, fetal tissue) in vitro as well as in the
fetal environment are required to evaluate proof-of-principle
strategies based on gene transfer or cell transplantation into the
fetus to ensure accurate organ-directed manipulation and delivery
(Moreno et al., 2012). Thus, the efficacy of treatment can be
evaluated from murine models to large animal models such as
sheep and primates (Mehta et al., 2012; Mehta and Abi-Nader,
2012).
Toxicology studies will be needed using animals such as the
pregnant rabbit, in which reproductive toxicology is commonly
performed, with good historical datasets and a model that is
understood by the regulators. A variety of guidelines and regu-
lations such as those described by the Committee for Medicinal
Products for Human Use (CHMP) of the European Medicines
Agency will need to be taken into consideration when planning
preclinical study protocols. These could include for example, the
guidelines on the non-clinical testing for inadvertent germline
transmission of gene transfer vectors (EU, 2006) or on the non-
clinical studies required before first clinical use of gene therapy
medicinal products (European Medicines Agency, 2007).
In addition to animal studies, the safety of gene therapy vectors
has to be evaluated. Integration site analysis has become a critical
tool to measure the “vector-on-host” and “host-on-vector” effects
in gene therapy (Biasco et al., 2011). Also, models such as the
human placenta can be utilized in vitro as it would provide a
wealth of data on the physiology of normal and pathological
human placentae and may be useful in measuring the spread of
vector from the fetus to the mother or vice versa.
CONCLUSION
Advances in prenatal screening and molecular diagnosis have
provided the ability of detecting the majority of genetic diseases
early in gestation. Early diagnosis provides the option of possible
treatment options that can be explored either at the prenatal
or postnatal period depending on the condition. The option of
preemptive treatment of congenital diseases in utero by stem cell
or gene therapy are encouraging as it changes the perspective of
congenital diseases. However, further work focusing on the safety
and ethical issues need to be addressed before clinical applications
can be considered.
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